摘要
目的比较含奈达铂(NDP)与含顺铂(DDP)联合化疗方案治疗中晚期卵巢癌的疗效和不良反应。方法2004年1月至2007年12月收治中晚期卵巢癌患者60例,分别进入奈达铂+环磷酰胺或顺铂+环磷酰胺组,分析两组的近期疗效及毒副作用。结果奈达铂组与顺铂组的近期有效率分别为46.7%和53.5%,差异无统计学意义(P>0.05);奈达铂组白细胞减少的发生率(46.7%)低于顺铂组(73.3%),差异有统计学意义(P<0.05);奈达铂组血小板减少发生率(36.7%)高于顺铂组(26.7%),但差异无显著性差异(P>0.05);两组间贫血发生率相近,无显著性差异(P>0.05);奈达铂组胃肠道反应发生率(30%)低于顺铂组(56.7%),差异有统计学意义(P<0.05);奈达铂组1例患者(3.3%)出现肝功能损害,顺铂组未发现肝功能损害。两组均未出现肾功能损害病例。奈达铂组尿β2-MG异常发生率(16.7%)低于顺铂组(36.7%),差异有统计学意义(P<0.05)。结论奈达铂+环磷酰胺为中晚期卵巢癌的有效化疗方案。
Objective To compare the efficacy and safety of Nedaplatin（NDP）-based regimen with cisplatin （DDP）-basod regimen on advanced ovarian cancer. Methods 60 patients with advanced ovarian cancer were given chemotherapy, nedaplatin ＋ cyclophos ＋ phamide or cisplatin ＋ cyclophosphamide. The efficacy and side-effects of 2 groups were observed. Results The effective rate were 46.7% and 53.5% in nedaplatin group and cisplaOn group（ P 〉 0.05 ）. Lcukopenia in nedaplatin group was weaker than that in cisplatin group （ P 〈 0. 05 ）, and the gastrointestinal toxicity was milder（ P 〈 0. 05 ）. Anemia were similiar in 2 groups. Hepatic toxicity appeared in one patient in nedaplatin group, while no hepatic toxicity appeared in cisplatin group. The urine β2-microglobulin elevation was more often in cisplatin group than that in the nedaplatin group （ P 〈 0. 05 ）. Conclusion Nedaplatin ＋ cyclophosphamide is an effective regimen for patients with advanced ovarian cancer.
出处
《实用药物与临床》
CAS
2009年第1期4-5,共2页
Practical Pharmacy and Clinical Remedies
关键词
卵巢肿瘤
奈达铂
顺铂
联合化疗
Ovarian neoplasms
Nedaplatin
Cisplatin
Comprehensive chemotherapy
